Linked Life Data

8619354

Source:http://linkedlifedata.com/resource/pubmed/id/8619354

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
1996-6-13
pubmed:abstractText
PURPOSE, MATERIAL AND METHODS: The clinical safety of iobitriodol 300 mg I/ml and iopromide 300 mg I/ml were compared in a randomized double blind phase-III study conducted on 60 patients undergoing abdominal CT for a variety of indications. Each examination was rated as diagnostic or nondiagnostic and the image quality was noted. Nature, onset, intensity as well as outcome of each adverse reaction were recorded. RESULTS: There was no significant difference in imaging quality and side effects between the contrast media. In this study, both iobitridol and iopromide provided excellent image quality and a low rate of side effects. CONCLUSION: Iobitridol is a safe and effective nonionic contrast agent for contrast-enhanced body CT.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0365-5954
pubmed:author
pubmed:issnType
Print
pubmed:volume
400
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
62-4
pubmed:dateRevised
2011-1-11
pubmed:meshHeading
pubmed:year
1996
pubmed:articleTitle
Iobitridol 300 compared to iopromide 300--a double-blind randomized phase-III study of clinical tolerance in total body CT.
pubmed:affiliation
Department of Radiology, Canton Hospital, Fribourg, Switzerland.
pubmed:publicationType
Journal Article, Clinical Trial, Comparative Study, Randomized Controlled Trial, Clinical Trial, Phase III